APOHEALTH DESLORATADINE desloratadine 5 mg tablet blister pack (new formulation)

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

desloratadine, Quantity: 5 mg

Disponibbli minn:

Arrotex Pharmaceuticals Pty Ltd

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: dibasic sodium phosphate; lactose monohydrate; pregelatinised starch; magnesium stearate; maize starch; colloidal anhydrous silica; microcrystalline cellulose; hydrogenated cottonseed oil; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin; indigo carmine aluminium lake

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

5, 3, 14, 42, 60, 2, 15, 50, 30, 10, 25, 28, 40, 45, 20, 7

Tip ta 'preskrizzjoni:

(S2) Pharmacy Medicine

Indikazzjonijiet terapewtiċi:

The rapid relief of symptoms associated with seasonal allergic rhinitis. The nasal symptoms of allergic rhinits include rhinorrhoea, sneezing and nasal itching. Allergic rhinitis is also associated with non-nasal symptoms such as ocular itching, tearing and itching of the eyes or palate. The relief of symptoms associated with perennial allergic rhinitis. The symptomatic relief of itching and reduction in the size and number of hives associated with chronic idiopathic urticaria.

Sommarju tal-prodott:

Visual Identification: Blue, round, biconvex tablets; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2022-03-16